Small Business High-Priority Areas of Interest
NIAID's divisions are particularly interested in applications that address the areas listed below. Also read NIAID's section of the Small Business Program Descriptions and Research Topics.
Division of AIDS -- Small Business High-Priority Areas of Interest
Updated April 13, 2009.
| Areas of Interest |
Subject Matter Expert |
Email |
Phone |
| Preclinical development and evaluation of HIV vaccines, adjuvants, delivery systems, vaccines that induce mucosal immunity and broadly reactive neutralizing antibodies, and novel technologies (e.g., nanotechnology) to enhance vaccine potency to prevent HIV infection or disease. |
Yen Li |
yli@niaid.nih.gov |
301-496-3816 |
| Development of anti-HIV agents directed at new viral or cellular targets. |
Paul Black |
pblack@niaid.nih.gov |
301-496-2970 |
| Development of novel anti-HIV drugs and therapeutics with focus on technological aspects such as multiplex analysis of drugs and innovative, streamlined methods for drug screening and drug delivery (e.g., multifunctional therapeutics based on nanotechnology). Development of bio-assay and bio-imaging applications for the assessment of HIV pathogenesis. |
Kailash Gupta |
kgupta@niaid.nih.gov |
301-435-3724 |
| Preclinical microbicide development of combination
microbicides (multiple compounds, targets of activity against HIV and STIs associated with HIV acquisition); new chemical classes with specific mechanisms of action and antiviral targets, new microbicide targets, and formulation
and delivery approaches for new and existing microbicides, including nanotechnology-based approaches. |
Jim A. Turpin |
jturpin@niaid.nih.gov |
301-451-2732 |
| Development, standardization, validation and evaluation of improved technologies to detect HIV, to evaluate immune responses to HIV vaccines and to vaccine vectors, or to correlate immune responses associated with vaccine efficacy. |
Marco Schito, Contractor, Henry M. Jackson Foundation |
schitom@niaid.nih.gov |
301-594-5374 |
| Development and evaluation of practical and affordable tests to measure viral load, CD4+ cell counts, and drug toxicities and drug resistance to monitor populations in resource-poor settings. Development of tests to detect early infection in seropositive HIV-infected individuals. |
Michael Ussery |
mussery@niaid.nih.gov |
301-402-0134 |
| Preclinical discovery and development of antimicrobial agents directed against Mycobacterium avium, Pneumocystis pneumonia, and Cryptococcus neoformans (and other pathogenic fungi). Development and delivery of nanotechnology-based therapeutics to target pathogen or pathogen-infected cells. Influence of antiretrovirals (e.g., ritonavir) on antimicrobial efficacy. |
Chris Lambros |
cl29r@nih.gov |
301-435-3769 |
| Preclinical development and evaluation of therapeutic vaccines and other immune-based therapies to attenuate HIV disease progression or reduce HIV infectiousness. |
Tony Conley |
conleyto@niaid.nih.gov |
301-451-2739 |
| Development of gene therapies for HIV. |
Frosso Voulgaropoulou |
frossov@mail.nih.gov |
301-451-2704 |
| Research to assess and overcome specific biomedical obstacles in HIV vaccine discovery, especially by application of novel technology to vaccine discovery and/or by the development and supply of novel reagents and other resources useful in novel vaccine discovery. |
Stuart Shapiro |
sshapiro@niaid.nih.gov |
301-402-0122 |
| Discovery and development of agents or strategies for Pre-exposure prophylaxis (PrEP) (single or multiple agents, immunological, pharmacological, or other potential approaches directed against viral and/or host targets). Development of pharmacological tools to examine PK/PD in fluids and tissue, new formulation and delivery systems (including nanotechnology-based approaches) for coitally-dissociated use, and optimization of animal models for screening of candidate agents. |
David Burns |
burnsda@niaid.nih.gov |
301-435-8896 |
Nanotechnology imaging and sensing platforms for improved detection and characterization of latent HIV infection in reservoirs.
Multi-functional therapeutics developed or delivered using nanotechnology including systems to target HIV-infected cells and reservoirs. |
Steve Turk |
sturk@niaid.nih.gov |
301-435-3771 |
| Development of novel and improved assays that are highly sensitive, specific, and cost effective for the determination of HIV incidence. These diagnostic assays should: identify HIV infection before seroconversion, be based on B and non-B subtypes, require minimal operator effort and expertise, and include the development, incorporation, and validation of process controls. |
Usha Sharma |
usharma@niaid.nih.gov |
301-451-3441 |
Division of Allergy, Immunology, and Transplantation -- Small Business High-Priority Areas of Interest
Updated February 19, 2009.
| Areas of Interest |
Contact |
Email |
Phone |
| Development of medical countermeasures to protect against, mitigate, and treat the short- and long-term effects of radiation exposure due to terrorist attack. |
Andrea DiCarlo-Cohen |
ad292x@nih.gov |
301-451-9199 |
| Development of novel or improved decorporation agents to remove radionuclides from the body following accidental inhalation, ingestion or wound entry. |
David Cassatt |
dc458x@nih.gov |
301-451-3124 |
| Identification of radiation exposure biomarkers and development of new biodosimetry methods and devices for triage of radiation-exposed people. |
Narayani Ramakrishnan |
nr57h@nih.gov |
301-451-3101 |
| Novel approaches for detecting infants at
risk for developing asthma and other allergic diseases. |
Matthew Fenton |
fentonm@niaid.nih.gov |
301-496-8973 |
| Immune targets for asthma and allergic disease
interventions. Development of immunotherapies to prevent or treat allergic diseases. |
Matthew Fenton |
fentonm@niaid.nih.gov |
301-496-8973 |
| Single cell assays to isolate and study allergen-specific lymphocytes. |
Matthew Fenton |
fentonm@niaid.nih.gov |
301-496-8973 |
| Development of new reagents and non-murine animal models for allergy research. |
Matthew Fenton |
fentonm@niaid.nih.gov |
301-496-8973 |
| Innovative treatments for autoimmune diseases. |
Josiah Wedgwood |
jw472t@nih.gov |
301-496-7104 |
| Biomarkers to measure risk, disease activity,
and therapeutic response in autoimmune diseases. |
Josiah Wedgwood |
jw472t@nih.gov |
301-496-7104 |
| High throughput assay of T-cell activity
in autoimmune diseases. |
Josiah Wedgwood |
jw472t@nih.gov |
301-496-7104 |
| Standardized validated diagnostic criteria
and outcome measures for autoimmune diseases correlated with disease
activity. |
Josiah Wedgwood |
jw472t@nih.gov |
301-496-7104 |
| Innovative treatments for primary immunodeficiencies. |
Josiah Wedgwood |
jw472t@nih.gov |
301-496-7104 |
| Diagnostic tests to identify or screen for primary immunodeficiencies. |
Josiah Wedgwood |
jw472t@nih.gov |
301-496-7104 |
| Immunotherapeutic antibodies and agents against
bioterriorism pathogens (Category A-C). |
Helen Quill |
hq1t@nih.gov |
301-496-7551 |
| Biomarkers of host immune defense to bioterriorism
pathogens (Category A-C). |
Helen Quill |
hq1t@nih.gov |
301-496-7551 |
| Single cell assay for study of human immunology. |
Helen Quill |
hq1t@nih.gov |
301-496-7551 |
| Methods and analysis tools to facilitate high throughput, high resolution MHC typing in humans and non-human primates. |
Kristy Kraemer |
kkraemer@niaid.nih.gov |
301-496-5598 |
| Immunomodulatory agents to prevent graft rejection and biomarkers to predict transplantation outcomes. |
Nancy Bridges |
nbridges@niaid.nih.gov |
301-496-5598 |
Source animals, reagents, and diagnostic tools for xenotransplantation |
Crystal Koh |
ckoh@niaid.nih.gov |
301-496-5598 |
Division of Microbiology and Infectious Diseases -- Small Business High-Priority Areas of Interest
Updated November 20, 2009.
| Areas of Interest |
Contact |
Email |
Phone |
Development of more sensitive and accurate methods of direct detection of Borrelia burgdorferi for the purpose of diagnosing Lyme disease patients. Diagnostic approaches that contain one or more of the following are also encouraged: substantial and significant advances over conventional antibody-based approaches, methods that also take into account host response, and the ability to detect and differentiate multiple strains of Borrelia burgdorferi. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Vaccines for NIAID Category A, B, and C priority pathogens including influenza, Ebola, Marburg, arenavirus, and other viral encephalitides. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Vaccine development for tuberculosis, STIs, hepatitis B and C, and malaria and other high-impact global parasitic diseases. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Vaccine enhancement and formulation technologies with the goal of providing protection against multiple infectious disease agents, providing accelerated immune responses (more rapid schedules or reduced number of immunizations), increase ease of administration (i.e., self-administration), and increase product stability to minimize cold chain requirements. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Therapeutics for NIAID Category A, B, and C priority pathogens including smallpox, viral hemorrhagic fevers, viral encephalitides, botulinum neurotoxins, and influenza. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Therapeutics for tuberculosis, hepatitis B and C, and malaria and other high-impact global parasitic diseases. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Therapeutics exhibiting broad-spectrum activity against microbial pathogens. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Therapeutic enhancement and formulation technologies with the goal of improving drug development timeframes, productivity, efficacy, specificity, safety, stability, and delivery. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Diagnostics for point-of-care applications for NIAID Category A, B, and C priority pathogens including influenza and those causing emerging and re-emerging infectious diseases. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Diagnostics for tuberculosis, STIs, community acquired pneumonia, and malaria and other high impact, global parasitic diseases. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
| Vaccines, therapeutics, and diagnostics for emerging and re-emerging influenza viruses such as 2009 H1N1 influenza. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
|
|
